Emergent BioSolutions, Inc.

As of October 31, 2025, Emergent BioSolutions, Inc. shows a bullish trend supported by positive weekly MACD and Bollinger Bands, despite a mildly bearish KST on a monthly basis.

As of October 31, 2025, Emergent BioSolutions, Inc. has shifted to a bullish trend, supported by positive MACD signals and strong short-term performance, significantly outperforming the S&P 500 recently, despite longer-term underperformance.

As of October 31, 2025, Emergent BioSolutions, Inc. shows a bullish technical trend with strong short-term indicators, despite longer-term underperformance compared to the S&P 500.

As of August 27, 2025, Emergent BioSolutions, Inc. shows a mildly bullish trend with positive weekly and monthly MACD indicators, but caution is advised due to mixed signals from the KST and OBV, alongside underperformance compared to the S&P 500.

As of August 6, 2025, Emergent BioSolutions, Inc. has improved from a risky to an attractive valuation grade, indicating it may be undervalued with a current price of $7.94, a Price to Book Value of 0.67, and an EV to EBITDA of 14.99, suggesting potential for recovery and growth compared to its peers.

As of February 27, 2023, Emergent BioSolutions, Inc. is considered overvalued and risky, with a Price to Book Value of 0.67 and an EV to EBITDA ratio of 14.99, underperforming against peers and the S&P 500.

As of June 20, 2025, the market trend is mildly bearish due to daily moving averages, despite some positive momentum from weekly indicators and bullish Bollinger Bands on longer time frames.

As of March 2022, the management team of Emergent BioSolutions, Inc. includes Executive Chairman Fuad El-Hibri, President and CEO Robert Kramer, Lead Independent Director Ronald Richard, and Directors Seamus Mulligan, Marvin White, Independent Directors Sue Bailey and Zsolt Harsanyi. They oversee the company's strategic direction and operations.

Emergent BioSolutions, Inc. is a life sciences company focused on developing medical countermeasures for public health threats, with a market cap of $345.07 million and quarterly net sales of $222 million as of March 2025. Key financial metrics include a debt-to-equity ratio of 0.93 and a return on equity of -15.10%.

As of Jun 18, Emergent BioSolutions, Inc. has a market capitalization of 345.07 million, with net sales of 965.40 million and a net profit of -131.60 million over the latest four quarters.